Premium
The synergistic antitumor effect of recombinant interleukin‐1 and low‐dose of cyclophosphamide in tumor‐bearing mice
Author(s) -
Harada Takehisa,
Kan Norimichi,
Ichinose You,
Moriguchi Yoshio,
Li Li,
Sugie Tomoharu,
Okino Takashi,
Imamura Masayuki
Publication year - 1994
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930560109
Subject(s) - splenocyte , medicine , cyclophosphamide , interleukin 2 , pharmacology , in vivo , immunotherapy , in vitro , chemotherapy , ratón , immunology , cancer research , cytokine , immune system , biology , biochemistry , microbiology and biotechnology
Intraperitoneal (i. p.) treatment of MOPC104E ascitic tumor‐bearing BALB/c mice with interleukin‐1 (IL‐1) followed by a low dose of cyclophosphamide (CPA) resulted in synergistic prolongation of their survival time. This antitumor effect was abolished when administration of CPA preceded that of IL‐1. The combined i. p. therapy also eradicated subcutaneous (s. c.) tumors, indicating a systemically operating antitumor mechanism. In Winn assay, splenocytes from MOPC104E‐bearing mice treated with the combined therapy completely suppressed the growth of MOPC104E cells, but not that of another syngeneic tumor cell line, RL ♀ ‐8 cells. This tumor‐neutralizing activity was completely abrogated by treatment with anti‐asialo‐GM1 or anti‐Thy 1.2 and complement, and reduced by treatment with anti‐Lyt2.2 and complement. Treatment of splenocytes with 1‐leucine methyl ester (LeuOMe), which depletes natural killer (NK) cells and macrophages in vitro, did not affect the neutralizing activity. © 1994 Wiley‐Liss, Inc.